(Total Views: 467)
Posted On: 05/06/2021 2:22:10 PM
Post# of 148900
Yes, your right Sean. This is a valuable tool and if they didn't collect that data, IMO it's a planning failure for sure. That statistic is a fabulous marketing tool once we are approved for something.
Just think, when advertising Leronlimab in the future that 80%++ or more who were on Leronlimab for HIV combo or monotherapy during the pandemic, did not get Covid ensuring even more safety from a plague like disease and even more important if Corona Virus becomes an endemic like the flu. There are so many applications for Leronlimab that it's just mind boggling - GLTU
HCIT
Just think, when advertising Leronlimab in the future that 80%++ or more who were on Leronlimab for HIV combo or monotherapy during the pandemic, did not get Covid ensuring even more safety from a plague like disease and even more important if Corona Virus becomes an endemic like the flu. There are so many applications for Leronlimab that it's just mind boggling - GLTU
HCIT
(2)
(0)Scroll down for more posts ▼
